292 related articles for article (PubMed ID: 11136306)
21. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Chiti A; Spinelli A; Bombardieri E
Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
24. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
25. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
26. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
27. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
28. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; deHerder WW; vanEijck CH; Kwekkeboom DJ; deJong M; Pauwels S
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S219-23. PubMed ID: 10604135
[TBL] [Abstract][Full Text] [Related]
29. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
30. [Medical treatment of digestive neuroendocrine tumours].
Panzuto F; Nasoni S; Delle Fave G
Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
[TBL] [Abstract][Full Text] [Related]
31. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
[TBL] [Abstract][Full Text] [Related]
32. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
33. [Detection of somatostatin receptors in tumors in the area of the head and neck and their clinical importance].
Kau RJ; Wagner-Manslau C; Saumweber DM; Arnold W
Laryngorhinootologie; 1994 Jan; 73(1):21-6. PubMed ID: 7908199
[TBL] [Abstract][Full Text] [Related]
34. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.
Chalkia MT; Stefanoyiannis AP; Chatziioannou SN; Round WH; Efstathopoulos EP; Nikiforidis GC
Australas Phys Eng Sci Med; 2015 Mar; 38(1):7-22. PubMed ID: 25427548
[TBL] [Abstract][Full Text] [Related]
35. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
36. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
37. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
38. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
39. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.
Angeletti S; Corleto VD; Schillaci O; Marignani M; Annibale B; Moretti A; Silecchia G; Scopinaro F; Basso N; Bordi C; Delle Fave G
Gut; 1998 Jun; 42(6):792-4. PubMed ID: 9691916
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
